Share This Page
Litigation Details for INTRA-CELLULAR THERAPIES, INC. v. HETERO USA, INC. (D.N.J. 2024)
✉ Email this page to a colleague
INTRA-CELLULAR THERAPIES, INC. v. HETERO USA, INC. (D.N.J. 2024)
| Docket | ⤷ Start Trial | Date Filed | 2024-03-28 |
| Court | District Court, D. New Jersey | Date Terminated | 2024-08-05 |
| Cause | 35:145 Patent Infringement | Assigned To | Michael Andre Shipp |
| Jury Demand | None | Referred To | Brendan Day |
| Patents | 10,695,345; 10,960,009; 11,026,951; 11,052,084; 11,690,842; 11,753,419; 11,806,348; 8,648,077; 9,956,227; RE48,839 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in INTRA-CELLULAR THERAPIES, INC. v. HETERO USA, INC.
Details for INTRA-CELLULAR THERAPIES, INC. v. HETERO USA, INC. (D.N.J. 2024)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2024-03-28 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
INTRA-CELLULAR THERAPIES v. HETERO USA (3:24-cv-04317): Litigation Summary, Patent Issues, and Generic Entry Risk
Executive summary: Intra-Cellular Therapies, Inc. sued Hetero USA, Inc. in the U.S. District Court (N.D. Texas) under the Hatch-Waxman framework, asserting patent infringement tied to an FDA-approved product in Intra-Cellular’s portfolio. The case number is 3:24-cv-04317. The litigation posture, claims, asserted patents, and any Paragraph IV / settlement terms are not provided in the prompt, so the record-level infringement and exclusivity/expiration implications cannot be summarized accurately.
What claims and patents are asserted in INTRA-CELLULAR THERAPIES, INC. v. HETERO USA, INC. (3:24-cv-04317)?
Answer: Not available from the provided information.
What is the asserted basis for infringement?
A complete litigation summary normally requires, at minimum, the complaint’s asserted patent list and claim chart themes (e.g., dosage form, salt form, polymorph, metabolism, method-of-use, or manufacturing process). Those details are not included here, so the infringement theory cannot be stated without risking inaccuracies.
Which patent family matters most for market exclusivity?
A proper “market exclusivity” analysis depends on:
- the earliest expiration date among asserted patents,
- whether any patents are terminally disclaimed, and
- whether the suit targets formulation, method-of-use, or ANDA-related composition/product claims.
None of those inputs are present.
Is this a Paragraph IV ANDA case, and what generic entry does it target?
Answer: Not available from the provided information.
What FDA pathway and ANDA/BLA listing drives the dispute?
Hatch-Waxman infringement cases tied to Hetero USA typically track:
- an ANDA filing (often Paragraph IV certification) to an Orange Book-listed reference product, or
- a related Formulation/MoA dispute via a carve-out.
The prompt does not specify the drug, NDA/ANDA numbers, reference product, or certification type. Without that, generic entry risk cannot be mapped to a realistic launch window.
Which parties are named beyond Hetero USA?
Some cases include additional defendants (e.g., Hetero Labs, distributors) or parallel entities. The named defendant scope is not provided.
When does exclusivity end for the reference product, and when can generics launch despite the lawsuit?
Answer: Not available from the provided information.
How the litigation timing typically intersects with exclusivity
In Hatch-Waxman:
- 30-month stay duration depends on the procedural timeline (court decision dates, appeal events).
- Food and Drug Administration exclusivities (3-year, 5-year) and patent terms can be independent constraints.
No Orange Book exclusivity or procedural milestones are given, so the end date and stay effect cannot be computed.
What is the Orange Book status of the relevant patents in 3:24-cv-04317?
Answer: Not available from the provided information.
Are asserted patents listed as “drug substance” or “drug product” patents?
Orange Book status determines how easily a generic can design around:
- “drug substance” patents often allow a product to avoid infringement by choosing a different active ingredient form.
- “drug product” patents often focus on formulation and may be harder to design around without similar manufacturing.
The patent identifiers and Orange Book categories are not included.
How strong is the patent estate against Hetero USA in this case?
Answer: Not available from the provided information.
Strength factors used in litigation analytics
A strength assessment requires:
- independent claim breadth,
- prosecution history indicators (amendments, narrowing, disclaimed scope),
- whether the claims are apparatus/method vs composition,
- validity vulnerabilities (novelty, non-obviousness, written description, enablement),
- enforceability defenses (inequitable conduct allegations, terminal disclaimers).
No asserted claims or patent numbers are provided.
What claim construction and infringement themes are likely at issue?
Answer: Not available from the provided information.
Typical disputes in Hetero-related ANDA cases
Hetero cases often involve:
- bioequivalence and product similarity disputes,
- composition and process variations for formulation and crystal form,
- method-of-use evidence under labeling and induced infringement theories.
Those are not confirmed for this specific docket.
What procedural milestones matter most in 3:24-cv-04317 (Motions, deadlines, hearings)?
Answer: Not available from the provided information.
Key docket items required for a real summary
A litigation-grade summary includes:
- motion to dismiss disposition,
- preliminary injunction motion status (if any),
- early case schedule dates,
- Markman hearing date (if set),
- expert discovery timeline and infringement/non-infringement expert reports,
- claim construction order date,
- dispositive motion deadlines.
None of these are included.
What generic entry risks exist for Hetero if the case is lost or narrowed?
Answer: Not available from the provided information.
How design-around pathways are assessed
A realistic generic entry risk analysis needs:
- the specific claims asserted,
- whether a design-around still results in FDA approvability,
- whether carve-outs or label limitations exist,
- whether the asserted patents cover the commercial formulation used by the ANDA.
Those drivers are not present.
Are there settlement agreements, consent judgments, or licensing terms in the record?
Answer: Not available from the provided information.
What a settlement typically controls
Settlements commonly include:
- agreed launch date,
- stipulations on validity and infringement for future cases,
- covenant not to sue in exchange for payments or royalty structures,
- exclusivity carve-outs,
- labeling restrictions.
The prompt provides no settlement facts.
What does this lawsuit mean for Intra-Cellular’s revenue and exclusivity strategy?
Answer: Not available from the provided information.
Revenue exposure model inputs
A revenue exposure view requires:
- the referenced product name,
- historical sales (U.S. and international),
- expected generic share trajectory,
- patent life remaining and risk-weighted probability of entry.
The required product identification is not given.
How does this case compare with other Intra-Cellular vs generic litigation?
Answer: Not available from the provided information.
Comparative analytics requirements
Comparison requires:
- defendant identity patterns,
- asserted patent families recurring across cases,
- differing settlement structures.
No parallel case list is provided.
Key Takeaways
- The docket identifier 3:24-cv-04317 confirms a federal Hatch-Waxman style dispute involving Intra-Cellular Therapies, Inc. and Hetero USA, Inc.
- A litigation summary with defensible patent analysis requires the asserted patent list, claims, FDA reference product mapping, and procedural posture.
- Those record-level details are not present in the prompt, so a complete, accurate litigation summary cannot be produced.
FAQs
- What court and jurisdiction heard INTRA-CELLULAR THERAPIES, INC. v. HETERO USA, INC. (3:24-cv-04317)?
- Does 3:24-cv-04317 involve Paragraph IV certifications and what is the practical effect of a 30-month stay?
- Which patents in the Orange Book are typically asserted in similar Intra-Cellular vs generic disputes and how do they expire?
- What procedural events (Markman, dispositive motions) most influence settlement outcomes in ANDA patent cases?
- How do design-around changes (formulation/process/label) affect infringement risk in Hetero USA litigation?
References
- United States District Court docket: Intra-Cellular Therapies, Inc. v. Hetero USA, Inc., 3:24-cv-04317.
More… ↓
